IMAC Holdings Inc. Transforms Cancer Treatment with Innovative Subsidiary
IMAC Holdings Inc. Unveils Breakthrough in Precision Oncology
IMAC Holdings, Inc. proudly announces its innovative subsidiary, Ignite Proteomics LLC, focusing on precision oncology solutions. With the aim to optimize breast cancer treatment decision-making, Ignite Proteomics introduces a cutting-edge assay utilizing Reverse Phase Protein Array (RPPA) technology. This significant development follows the strategic acquisition of critical assets from Theralink Technologies, enhancing IMAC Holdings’ capabilities in the rapidly evolving healthcare landscape.
Transforming Cancer Treatment with Advanced Technology
Ignite Proteomics stands out by offering the only commercially available and clinically validated assay proficient in assessing both protein expression and activation levels in breast tumors. This innovative approach is a game-changer for evaluating the effectiveness of targeted cancer therapies. The clinical impact of Ignite’s pioneering proteomic assay is further exemplified through a notable case study involving a 57-year-old woman with metastatic triple-negative breast cancer (TNBC).
Case Study: Remarkable Response to Treatment
This patient had undergone multiple treatment regimens, including chemotherapy and targeted therapy, yet continued to experience disease progression across various regions of her body, including the brain and liver. Engaging with a clinical trial at Inova Schar Cancer Institute presented a unique opportunity to compare the effectiveness of Ignite’s RPPA technology against current next-generation sequencing (NGS) assays. Notably, the RPPA assay identified the expression and activation of HER2, a vital protein, which was overlooked in previous analyses.
Effective Treatment Outcomes
Without wasting time, the patient was placed on the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which relies heavily on HER2 expression for efficacy. After undergoing nine treatment cycles, remarkable results were observed: the patient exhibited no measurable disease, demonstrating a complete response to the therapy.
Leadership Insight: Commitment to Patient-Centric Care
Faith Zaslavsky, CEO of IMAC Holdings and Ignite Proteomics, expressed her enthusiasm about this advancement, stating, "The RPPA technology and our novel proteomics assay represent a transformative advancement in the management of breast cancer, providing critical insights that enable us to tailor treatments with greater precision and effectiveness. This case study's success emphasizes the potential of our assay to possibly enhance patient outcomes significantly."
About IMAC Holdings, Inc.
IMAC Holdings, Inc. is unequivocally dedicated to pioneering healthcare solutions that yield substantial improvements in patient care. With a commitment to strategic acquisitions and the development of innovative technologies, IMAC Holdings continues to be a vital player in advancing precision medicine.
About Ignite Proteomics
Ignite Proteomics LLC, an integral subsidiary of IMAC Holdings, specializes in state-of-the-art RPPA technology tailored for cancer diagnostics. As the exclusive provider of a CLIA-accredited RPPA assay for breast cancer, Ignite Proteomics benchmarks excellence in protein-centric testing and personalized oncology solutions.
Frequently Asked Questions
What is Ignite Proteomics?
Ignite Proteomics is a subsidiary of IMAC Holdings, focused on developing advanced RPPA technology for precision cancer diagnostics.
How does the new assay improve breast cancer treatment?
The assay enables clinicians to measure protein expression and activation levels, providing a clearer picture of treatment efficacy for breast cancer therapies.
What makes RPPA technology unique?
RPPA technology uniquely measures both expression and activated protein levels, offering a comprehensive profile that enhances treatment personalization.
What was the outcome of the case study?
The case study revealed a complete response to therapy in a patient who had unsuccessful outcomes from previous treatments, showcasing the assay's effectiveness.
Who leads IMAC Holdings and Ignite Proteomics?
Faith Zaslavsky serves as the CEO of both IMAC Holdings and Ignite Proteomics, driving initiatives in innovative healthcare solutions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.